Medication Monitor

Generic Name (Trade Name—Company)
May 10, 2011

Influenza virus vaccine

(Fluzone Intradermal—sanofi pasteur)
Intradermal influenza vaccine for adults


Active immunization against influenza virus in adults 18 to 64 years of age  

Sanofi pasteur announced the approval of the first influenza vaccine licensed in the United States that uses a novel microinjection system for intradermal delivery. Fluzone Intradermal differs from the I.M. formulation of Fluzone in that it features an ultrafine needle that is 0.06 inches in length and the vaccine contains 9 µg of hemagglutinin per strain of influenza in a 0.1 mL dose. The Fluzone I.M. formulation is administered using a needle 1 to 1.5 inches in length and contains 15 µg of hemagglutinin per strain of influenza in a 0.5 mL dose. In a Phase III clinical trial involving 4,276 adults, Fluzone Intradermal was found to induce immunologic responses that were comparable with the I.M. formulation. Since this new formulation deposits medication near the surface of the skin, local reactions occurred frequently, including redness, swelling, induration, pain, and pruritus. Fluzone Intradermal will be available during the upcoming 2011–12 influenza season.